Navigation Links
Evotec AG (DE) - Evotec Reports Positive Proof-of-Concept Top-Line,Results with ...

- Both co-primary endpoints, Wake After Sleep Onset and Total Sleep Time, and key secondary endpoints, including Latency to Persistent Sleep, were met at both doses - Evotec to host a conference call at 4pm CET (3pm UK time, 10am EST) today

HAMBURG, Germany | OXFORD, England, June 4, 2007-- Evotec AG (Frankfurt Stock Exchange: EVT) announced today positive top-line results from its first phase II clinical trial of EVT 201 in patients with chronic primary insomnia. EVT 201 is a partial positive allosteric modulator (pPAM) of the GABAA receptor complex. The double-blinded, placebo controlled cross-over study design of two doses of EVT 201 (1.5mg and 2.5mg) in 67 patients was conducted in sleep labs in the US using objective polysomnography. The pre-specified intention-to-treat analysis of the study showed statistically highly significant improvements between both doses of EVT 201 and placebo in both of the co-primary endpoints of Total Sleep Time (TST) (p<0.001) and Wake After Sleep Onset (WASO) (p<0.001). Notably, WASO during the second half of the night was also significantly (p<0.001) reduced, indicating that EVT 201 has efficacy in sleep maintenance throughout the night.

Improvements were also seen across pre-specified secondary endpoints. Latency to persistent sleep was markedly decreased by both doses of EVT 201 (p<0.001) and patients reported highly significant improvements in subjectively assessed quality of sleep (p<0.001 both doses). Treatment with EVT 201 was completely without effect on subjectively assessed residual sedation the next day and produced only a small decremental effect on the digital symbol substitution test (DSST) assessed at nine hours post dosing. Initial analysis showed that EVT 201 did not impair slow wave sleep unlike many benzodiazepine full agonists. The study therefore demonstrated EVT 201 has robust effects on both sleep onset and sleep maintenance and is without
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Evotec Reports Positive Proof-of-Concept Top-Line Results with Insomnia Drug Candidate EVT 201
2. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
3. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
4. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
5. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
6. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
7. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
8. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
9. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
10. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
11. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Evotec Evotec Reports Positive Proof Concept Top Line Results with
(Date:9/17/2014)... Sept. 17, 2014 Research and Markets ... Breast Cancer Market 2014-2018" report to their offering. ... uncontrolled growth of cancerous cells in the breast tissue. ... breast cancer is rare. Histologically, breast cancer can be ... other undifferentiated carcinoma. Ductal carcinoma is the form of ...
(Date:9/17/2014)... Switzerland , September 17, 2014 ... is proud to congratulate Biocartis commitment in shipping ... is a long-time investor in Biocartis as part ... Biocartis, fully automated, real-time PCR based molecular ... and easy access to clinical molecular diagnostic information, ...
(Date:9/16/2014)... Massachusetts , 17. September 2014 ... HOLX ), hat heute die ... zur präanalytischen Probenverarbeitung, in Europa bekannt ... gekennzeichnete, vollautomatisierte Universalplattform zur Vereinfachung der ... dass ineffiziente und fehlerbehaftete Arbeitsschritte bei ...
Breaking Medicine Technology:Global Breast Cancer Market 2014-2018: Key Vendors are Astrazeneca, Eli Lilly and Company and F. Hoffmann-La Roche, Novartis and Sanofi-Aventis 2Global Breast Cancer Market 2014-2018: Key Vendors are Astrazeneca, Eli Lilly and Company and F. Hoffmann-La Roche, Novartis and Sanofi-Aventis 3Debiopharm Diagnostics Portfolio Company Biocartis Ships its First Idylla Instrument 2Hologic stellt in Europa den Tomcat vor, ein neues Gerät zur präanalytischen Probenverarbeitung 2Hologic stellt in Europa den Tomcat vor, ein neues Gerät zur präanalytischen Probenverarbeitung 3
... KARLSRUHE, Germany, March 4, 2011 The High Court of ... favor of AmniSure® International, LLC in its dispute with the ... Court,s ruling that the patent associated with Medix,s ActimPROM test ... inventive step. Medix is expected to pay AmniSure® an undisclosed ...
... -- Bacterin International Holdings, Inc. (OTC Bulletin Board: ... revolutionary bone graft material and anti-infective coatings for medical applications, ... listing on the NYSE Amex and has chosen Knight Capital ... stock will commence trading on the NYSE Amex on Monday, ...
Cached Medicine Technology:German High Court Rules in Favor of AmniSure® as New European Guidelines Published 2Bacterin International Holdings, Inc. Receives Approval for Listing on NYSE Amex 2Bacterin International Holdings, Inc. Receives Approval for Listing on NYSE Amex 3
(Date:9/17/2014)... Calif. (PRWEB) September 17, 2014 ... monthly interruptions, giving girls of all ages an ... wellness company founded by women, for women, announces ... Uninterrupted® (http://GirlU.com) to relieve the symptoms ... bloating and irritability. , As a lifelong ...
(Date:9/17/2014)... 17, 2014 In a new video ... William Groff, an expert on the condition known as PPP, ... penile papules , or PPP, is a condition that affects ... men may be affected as well. The condition is characterized ... , “While PPP is not a sexually transmitted disease and ...
(Date:9/17/2014)... (PRWEB) September 17, 2014 A raucous ... Disease come together to form author Nancy Chovancek’s laughter-filled ... book is a collection of short stories that prove ... on fun. With a positive message of empowerment and ... Chovancek is a proven author with two books under ...
(Date:9/17/2014)... GA (PRWEB) September 17, 2014 ... District (DHCHD) has implemented its CollaborNet™ Health ... exchange of patients’ health information between Coon Memorial ... Texas, and physicians in the community. , ... application to enable electronic referrals by physicians to ...
(Date:9/17/2014)... Seattle, Wa (PRWEB) September 17, 2014 ... published by the Telegraph in August 2014, scientists made ... cure for diabetes, but still failed. The article indicates ... , Despite this existing fact, there are many forward-thinking ... for diabetes treatment in a natural way. Dr. Kenneth ...
Breaking Medicine News(10 mins):Health News:Girl Uninterrupted® Debuts New Look for All-Natural, PMS-Relief Supplement, Launching Today 2Health News:Girl Uninterrupted® Debuts New Look for All-Natural, PMS-Relief Supplement, Launching Today 3Health News:Girl Uninterrupted® Debuts New Look for All-Natural, PMS-Relief Supplement, Launching Today 4Health News:New Video Depicts Best Treatment for PPP 2Health News:New Video Depicts Best Treatment for PPP 3Health News:Dallam-Hartley Counties Hospital District Deploys Holon's Health Information Exchange (HIE) Solution to Facilitate Improved Patient Care 2Health News:Dallam-Hartley Counties Hospital District Deploys Holon's Health Information Exchange (HIE) Solution to Facilitate Improved Patient Care 3Health News:Discover a Safe and Effective Treatment for Diabetes with The Diabetes Protocol – Vinamy 2
... 5 seek any assistance, MORAGA, Calif., Oct. 9 ... common disorders, it is regularly under diagnosed by,medical professionals., ... -- muscle tension,headache, nausea, fatigue, or trembling -- before ... during times of stress such as a,divorce, job change ...
... Results of a multicenter study led by Johns Hopkins ... babies with hydrocortisone, a steroid believed to fight inflammation ... treatment offers little or no benefit and that low ... levels, on the other hand, appeared to increase the ...
... New Report Shows Only 17% of Employers Offer Vision Benefits, ... have taken center stage in the upcoming election, worries about,the ... minds of most,Americans. For the 120 million Americans with vision ... value on maintaining healthy vision,the lack of vision coverage is ...
... Generations agrees to sell patents to Life Spine, ... firm Life Spine, Inc. announced today that it has ... LLC. Terms of,the transaction were not disclosed., According ... property expansion is critical. "The core of the spine ...
... Oct. 8 The Hain Celestial,Group, Inc. (Nasdaq: ... food and personal,care products company, today announced that ... to make a presentation regarding the,Company on Wednesday, ... Natural Boston Conference., (Logo: http://www.newscom.com/cgi-bin/prnh/20050324/NYTH131 ...
... Predictive medicine company,PreMD Inc. (TSX: PMD; PREMF.pk) ... has completed its previously announced debenture financing ... Midsummer,Investment, Ltd. The gross proceeds of the ... general corporate purposes., "We are very ...
Cached Medicine News:Health News:40 Million Americans Endure Anxiety Everyday 2Health News:Steroid treatment offers no benefit in preemies, Hopkins Children's study suggests 2Health News:Steroid treatment offers no benefit in preemies, Hopkins Children's study suggests 3Health News:Americans Place High Value on Eyesight, Yet Many Still Lack Vision Coverage 2Health News:Americans Place High Value on Eyesight, Yet Many Still Lack Vision Coverage 3Health News:Hain Celestial to Present at Canaccord Adams Healthy Living Naturally Boston Conference on October 15, 2008 2Health News:PreMD Inc. Completes Secured Debenture Financing 2
Cholesterol FS. For determination of cholesterol in serum or plasma. Available with Calibrator: Trucal U and Controls: Trulab N, Trulab P Trulab L....
Intended for the quantitative determination of total cholesterol in serum. Single vial, dry powder reagent. Reaction: Endpoint. Wavelength: 500 nm. Linearity: 700 mg/dL (12.9 mmol/L)....
This true 8-bit integrated and cooled imaging system is a completely self contained unit built with a long list of standard features including all-electronic-variable transilluminator and EPI lightin...
... range of Platelet aggregometers allows to ... particular needs. Single, dual and four ... recorder outputs or digital computer outputs. ... aggregometers, which measure platelet aggregation in ...
Medicine Products: